Investigating how TET2 regulates blood stem cells through RNA modifications
Critical roles of RNA m5C-MBD6-H2AK119ub deubiquitylation axis in TET2-mediated HSC regulation
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-10937700
This study is looking at how a protein called TET2 helps control blood stem cells, which are important for making blood cells, and it hopes to find new ways to improve treatments for blood disorders like myeloid cancers.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-10937700 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the TET2 protein in regulating hematopoietic stem and progenitor cells (HSPCs), which are crucial for blood cell formation. The study examines how TET2 influences RNA modifications and chromatin states, potentially affecting the self-renewal and differentiation of these stem cells. By exploring the interactions between TET2, RNA, and specific proteins, the research aims to uncover new mechanisms that could lead to better treatments for blood-related disorders. Patients may benefit from insights gained about how to manage conditions like myeloid malignancies.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults with myeloid malignancies or those experiencing clonal hematopoiesis.
Not a fit: Patients with non-hematological conditions or those outside the age range of 21+ years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for patients with blood cancers and other hematological conditions.
How similar studies have performed: Previous research has shown promising results in understanding RNA modifications and their impact on cell regulation, suggesting that this approach could yield valuable insights.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XU, MINGJIANG — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: XU, MINGJIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.